moneyheap
EWTX · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Edgewise Therapeutics, Inc. Common Stock (EWTX) stock moving?
EWTX closed at $46.53 on Nov 10, up about 24% from $37.53 on Nov 4 and off a $48.74 high on Nov 9. The move began on Nov 5, when volume reached 5.2M shares against a typical 1.0-1.9M, after the company said FDA end-of-Phase 2 feedback supported the EDG-7500 Phase 3 design in hypertrophic cardiomyopathy and that the STRATUS-HCM protocol had been submitted. Wedbush kept its Outperform rating and trimmed its target to $51 from $53, which still sits above the current price. Rumors of takeover interest on Nov 6 and a report on Nov 8 that the company is exploring a sale have added momentum, but neither is confirmed by the company. The Q3 report on Nov 4 showed an adjusted EPS of $(0.19), which Benzinga reported as a miss against a $2.48 estimate, though for a clinical-stage company that figure matters less than pipeline progress. The Phase 3 start is targeted by year-end 2026, and the EQUINOX-HFpEF Phase 2 trial has begun dosing. The stock is now pulling back from its high on lighter volume, so the sale story is the main driver of the gain and carries the most uncertainty.
News behind the analysis
- Edgewise Therapeutics to Participate in Upcoming Investor ConferencesManagement will present at the Guggenheim 3rd Annual Healthcare Innovation Conference and the 2026 Truist Biopharma Symposium.
- Edgewise Therapeutics Reportedly Explores Potential SaleReports say Edgewise is exploring a sale and may have hired advisers for a formal sales process. The report is unconfirmed by the company.
- Watching Edgewise Therapeutics; Shares Trading Higher, Traders Circulate Unconfirmed Rumor From M&A Blog Suggesting The Co Is Seeing Takeover InterestShares traded higher on an unconfirmed M&A blog rumor that Edgewise is attracting takeover interest.
- Wedbush Adjusts Price Target for Edgewise TherapeuticsWedbush kept its Outperform rating and lowered its price target from $53 to $51.
- Edgewise Therapeutics Announces Favorable FDA End-of-Phase 2 Meeting for EDG-7500FDA feedback supports the EDG-7500 Phase 3 design in hypertrophic cardiomyopathy, using tolerability-based dose escalation without mandatory safety echo monitoring.
- Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $51Wedbush reiterated Outperform on Edgewise and cut its price target to $51 from $53.
- Edgewise Therapeutics Says Edgewise Has Submitted STRATUS-HCM Phase 3 Protocol Following End-Of-Phase 2 MeetingEdgewise has submitted the STRATUS-HCM Phase 3 protocol for EDG-7500 following the end-of-Phase 2 meeting with FDA.
- Edgewise Therapeutics Reports Third Quarter 2026 Financial ResultsEdgewise reported Q3 2026 results and updates, including the EDG-7500 Phase 3 start targeted by year-end 2026 and the first patient dosed in the EQUINOX-HFpEF trial.
- Edgewise Therapeutics Q3 Adj. EPS $(0.19) Misses $2.48 EstimateReported adjusted EPS of $(0.19) for Q3, against a $2.48 estimate cited by Benzinga.
About Edgewise Therapeutics, Inc. Common Stock
Edgewise Therapeutics is a clinical-stage biotech based in Boulder, Colorado, that develops drugs targeting the sarcomere, the part of the cell that makes muscle contract, and it now focuses on heart disease. In July 2026 it sold its muscular dystrophy business, including the drug sevasemten, to Servier and now concentrates on heart drugs such as EDG-7500 (for hypertrophic cardiomyopathy) and EDG-15400 (for heart failure).
How it makes money
It has no approved products and essentially no product revenue, so it pays for research with cash raised from investors and from deals. Selling sevasemten to Servier brought a one-time gain of roughly $1.35 billion in Q3 2026, which made that quarter's net income positive. Cash and investments were about $1.7 billion as of September 30, 2026. Any future revenue would come from approved drugs or partnership deals.
What usually moves EWTX
- EDG-7500 clinical trial data and Phase 3 plans in hypertrophic cardiomyopathy
- Progress of the EDG-15400 Phase 2 heart failure trial
- FDA regulatory decisions
- Cash runway and spending on research
- Rival cardiac myosin drugs and overall biotech sentiment